Covance IncCovance Inc, Medical Devices Deals, 2011 to YTD 2017 Covance Inc, Medical Devices Deals,...

Covance Inc

Pharmaceuticals & Healthcare - Deals and Alliances Profile

Report Code: GDPH4011D Published: November 2017

Covance Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile


© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form

Company Snapshot

Company Overview Covance Inc (Covance), a subsidiary of LabCorp, is a drug development company that offers contract research and manufacturing services. The company offers a broad range of early-stage and late-stage product development services to pharmaceutical, biotechnology and medical device companies. It also offers services including laboratory testing for agrochemical, chemical and food industries. The early-stage development services that the company offers include preclinical and clinical pharmacology services and discovery support services. Its late-stage development services include Phase II-IV clinical development, central laboratory and market access services.

Key Facts

Covance Inc, Pharmaceuticals & Healthcare, Key Facts

Web Address Revenue (US$ million) Number of Employees GlobalData

Financial Deals Landscape Covance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

Note: Deals include all announced pharmaceuticals & healthcare deals from 2011 onwards, GlobalData

Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017


Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017


Covance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017





Table of Contents

Table of Contents ............................................................................................................................................................................... 3 List of Tables .................................................................................................................................................................................. 5 List of Figures ................................................................................................................................................................................ 5

Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 ............................................................................... 7 Covance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 ................................................................................ 8 Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017............................................................................ 9 Covance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 ............................................................... 10 Covance Inc, Medical Devices Deals, 2011 to YTD 2017 .................................................................................................................. 11 Covance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 .......................................................................... 12 Covance Inc, Pharmaceuticals & Healthcare, Deal Details .............................................................................................................. 13

Private Equity .............................................................................................................................................................................. 13 Chicago Growth Partners Acquires Caprion Proteomics For US$29 Million .......................................................................... 13

Partnerships ................................................................................................................................................................................ 14 Emulate Enters into Agreement with Covance ...................................................................................................................... 14 Motif Bio Enters into Agreement with Covance ..................................................................................................................... 15 Covance Enters into Co-Development Agreement with Sihuan Pharma ............................................................................... 16 Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research .................................. 17 Covance Enters into Research Agreement with Frenova Renal Research ............................................................................. 18 Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments.......................................... 19 Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials ............. 20 GNS Healthcare Enters Into Co-Development Agreement With Covance ............................................................................. 21 Bayer HealthCare Enters Into Agreement With Covance ....................................................................................................... 22 Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative .......................... 23 Covance Enters Into Research Agreement With Institute for Systems Biology For Tumor Biology ....................................... 24 Ingenuity Systems Enters Into Research Collaboration With Covance Genomics ................................................................. 25 Takeda Enters Into Co-Development Agreement With Covance ........................................................................................... 26

Debt Offering .............................................................................................................................................................................. 27 Covance Completes Private Placement Of Notes Due 2023 For US$90 Million ..................................................................... 27 Covance Completes Private Placement Of Notes Due 2018 For US$15 Million ..................................................................... 28 Covance Completes Private Placement Of Notes Due 2020 For US$50 Million ..................................................................... 29 Covance Completes Private Placement Of Notes Due 2025 For US$95 Million ..................................................................... 30

Asset Transactions ...................................................................................................................................................................... 31 LabCorp Acquires High-Complexity Genomic Lab From Covance .......................................................................................... 31

Acquisition................................................................................................................................................................................... 32 LabCorp Acquires Chiltern International for USD1.2 Billion ................................................................................................... 32 Chiltern International Acquires Integrated Development Associates .................................................................................... 34 LabCorp Acquires Covance for USD6.1 Billion ........................................................................................................................ 35 Chiltern International Acquires Pacific Clinical Research ....................................................................................................... 37 BioLegend Acquires Covance Antibody Services from Covance ............................................................................................. 38 Chiltern Acquires Ockham, Contract Research Organization ................................................................................................. 39 Covance Acquires Medaxial.................................................................................................................................................... 40 Kester Capital Sells Its Stake In Chiltern For US$220 Million.................................................................................................. 41 Smithers Viscient Services Completes Acquisition Of Environmental Sciences From Covance ............................................. 42 Covance Acquires Trac Microbiology, Microbiology And Chemistry Laboratory ................................................................... 43 Chiltern International Acquires Additional Stake In Endpoint ............................................................................................... 44

Covance Inc - Key Competitors ........................................................................................................................................................ 45 Covance Inc - Key Employees ........................................................................................................................................................... 46 Covance Inc - Locations And Subsidiaries ........................................................................................................................................ 47

Head Office.................................................................................................................................................................................. 47 Other Locations & Subsidiaries ................................................................................................................................................... 47

Recent Developments ...................................................................................................................................................................... 49 Appendix .......................................................................................................................................................................................... 50




Methodology ............................................................................................................................................................................... 50 About GlobalData ........................................................................................................................................................................ 50 Disclaimer .................................................................................................................................................................................... 50




List of Tables

Covance Inc, Pharmaceuticals & Healthcare, Key Facts..................................................................................................................... 2 Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 ............................................................................... 7 Covance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 ................................................................................ 8 Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017............................................................................ 9 Covance Inc, Deals By Therapy Area, 2011 to YTD 2017 ................................................................................................................. 10 Covance Inc, Medical Devices Deals, 2011 to YTD 2017 .................................................................................................................. 11 Covance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 .......................................................................... 12 Chicago Growth Partners Acquires Caprion Proteomics For US$29 Million .................................................................................... 13 Emulate Enters into Agreement with Covance ................................................................................................................................ 14 Motif Bio Enters into Agreement with Covance .............................................................................................................................. 15 Covance Enters into Co-Development Agreement with Sihuan Pharma ......................................................................................... 16 Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research ........................................... 17 Covance Enters into Research Agreement with Frenova Renal Research ....................................................................................... 18 Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments ................................................... 19 Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials ....................... 20 GNS Healthcare Enters Into Co-Development Agreement With Covance ....................................................................................... 21 Bayer HealthCare Enters Into Agreement With Covance ................................................................................................................ 22 Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative ................................... 23 Covance Enters Into Research Agreement With Institute for Systems Biology For Tumor Biology ................................................ 24 Ingenuity Systems Enters Into Research Collaboration With Covance Genomics ........................................................................... 25 Takeda Enters Into Co-Development Agreement With Covance ..................................................................................................... 26 Covance Completes Private Placement Of Notes Due 2023 For US$90 Million .............................................................................. 27 Covance Completes Private Placement Of Notes Due 2018 For US$15 Million .............................................................................. 28 Covance Completes Private Placement Of Notes Due 2020 For US$50 Million .............................................................................. 29 Covance Completes Private Placement Of Notes Due 2025 For US$95 Million .............................................................................. 30 LabCorp Acquires High-Complexity Genomic Lab From Covance .................................................................................................... 31 LabCorp Acquires Chiltern International for USD1.2 Billion ............................................................................................................ 32 Chiltern International Acquires Integrated Development Associates ............................................................................................. 34 LabCorp Acquires Covance for USD6.1 Billion ................................................................................................................................. 35 Chiltern International Acquires Pacific Clinical Research................................................................................................................. 37 BioLegend Acquires Covance Antibody Services from Covance ...................................................................................................... 38 Chiltern Acquires Ockham, Contract Research Organization .......................................................................................................... 39 Covance Acquires Medaxial ............................................................................................................................................................. 40 Kester Capital Sells Its Stake In Chiltern For US$220 Million ........................................................................................................... 41 Smithers Viscient Services Completes Acquisition Of Environmental Sciences From Covance ....................................................... 42 Covance Acquires Trac Microbiology, Microbiology And Chemistry Laboratory ............................................................................. 43 Chiltern International Acquires Additional Stake In Endpoint ......................................................................................................... 44 Covance Inc, Key Competitors ......................................................................................................................................................... 45 Covance Inc, Key Employees ............................................................................................................................................................ 46 Covance Inc, Other Locations .......................................................................................................................................................... 47 Covance Inc, Subsidiaries ................................................................................................................................................................. 48

List of Figures

Covance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 ............................................................................... 2 Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 ............................................................................... 2 Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017............................................................................ 2 Covance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 ................................................................. 2 Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 ............................................................................... 7 Covance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 ............................................................................... 8




Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017............................................................................ 9 Covance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 ............................................................... 10 Covance Inc, Medical Devices Deals, 2011 to YTD 2017 .................................................................................................................. 11






Note: Deals include all announced pharmaceuticals & healthcare deals from 2011 onwards, deal values included wherever disclosed. GlobalData


Year No. of Deals Deal Value (US$ million)

2011

2012

2013

2014

2015

2016

YTD 2017

Note: Deals include all announced pharmaceuticals & healthcare deals from 2011 onwards, deal values included wherever disclosed. Above data is extracted from GlobalData’s Deals and Alliances Profile.

GlobalData




Covance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017

Covance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

Note: Deals include all announced pharmaceuticals & healthcare deals from 2011 onwards GlobalData

Covance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017

Deal Type No. of Deals Deal Value (US$ million)









Region No. of Deals Deal Value (US$ million)








Covance Inc, Deals By Therapy Area, 2011 to YTD 2017

Therapy Area No. of Deals Deal Value (US$ million)





Covance Inc, Medical Devices Deals, 2011 to YTD 2017




Device Type No. of Deals Deal Value (US$ million)

Note: Deals include all announced pharmaceuticals & healthcare deals from 2011 onwards, deal values included wherever disclosed.

GlobalData




Covance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017

Covance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017

Deal Date Deal Status Deal Type Acquirer / Investor / Licensor

Target / Issuer / Partners / Licensee

Vendor Deal Value (US$ m)

Note: Deals include all pharmaceuticals & healthcare deals from 2011 onwards, deal values included wherever disclosed. GlobalData




Covance Inc, Pharmaceuticals & Healthcare, Deal Details

Private Equity

Chicago Growth Partners Acquires Caprion Proteomics For US$29 Million

Chicago Growth Partners Acquires Caprion Proteomics For US$29 Million

Deal Type Deal Sub Type

Deal in Brief

."

Deal Information

Deal Status

Completed Date

Deal Financials

Deal Payment

Companies Information

Vendor Company Information

Company Name

Company Name Parent

Business Description

Target Company Information

Company Name


Investor Firm Information

Firm Name

Vendor Firm Information

Firm Name GlobalData




Partnerships

Emulate Enters into Agreement with Covance

Emulate Enters into Agreement with Covance


Deal in Brief

.

Deal Rationale

.

Deal Information

Deal Status

Completed Date


Partner Company Information

Company Name Parent


Company Name Emulate Inc GlobalData




Motif Bio Enters into Agreement with Covance

Motif Bio Enters into Agreement with Covance


Deal in Brief

).

Deal Rationale

Deal Information

Deal Status

Completed Date



Company Name Parent


.

Company Name GlobalData




Covance Enters into Co-Development Agreement with Sihuan Pharma

Covance Enters into Co-Development Agreement with Sihuan Pharma


Deal in Brief

Deal Rationale

.

Deal Information

Deal Status

Completed Date



Company Name Parent


Company Name


.

Company Name Parent


. GlobalData



© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form Page 45

Covance Inc - Key Competitors

Covance Inc, Key Competitors

Name Headquarters Revenue (US$ m)

Source: Annual Report, Company Website, Primary and Secondary Research GlobalData




Covance Inc - Key Employees

Covance Inc, Key Employees

Name Job Title Board Level Since Age





Covance Inc - Locations And Subsidiaries

Head Office

Covance Inc

210 Carnegie Center

Princeton

NJ

08540

United States

Tel: +1 609 4524440

Fax: +1 609 4529375

Other Locations & Subsidiaries

Covance Inc, Other Locations





Covance Inc, Subsidiaries





Recent Developments




Appendix

The data and analysis within this report is driven by GlobalData.

GlobalData gives you the key information to drive sales, investment and deal making activity in your business.

Our coverage includes 200,000 + reports on 185,000+ companies (including 150,000+ private) across 200+ countries and 29 industries. The key industries include Alternative Energy, Oil & Gas, Clean Technology, Technology and Telecommunication, Pharmaceutical and Healthcare, Power, Financial Services, Chemical and Metal & Mining.

Methodology

GlobalData company reports are based on a core set of research techniques which ensure the best possible level of quality and accuracy of data. The key sources used include:

• Company Websites

• Company Annual Reports

• SEC Filings

• Press Releases

• Proprietary Databases

Notes

• Financial information for the company is taken from the most recently published annual reports or SEC filings

• The financial and operational data reported for the company is as per the industry defined standards

• Currencies are converted at current rates, with average annual rates taken for historic conversions

Deals includes all announced deals from 2011 onwards, deal values are included wherever disclosed.

About GlobalData

GlobalData is one of the world’s leading providers of company operational data and strategic analysis, providing detailed information on tens of thousands of companies globally. Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge. Data is continuously updated and revised by large teams of research experts, so that it always reflects the latest events and information. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research material for this series and its other reports. GlobalData offers comprehensive geographic coverage across world’s most important sectors, focusing particularly on energy and healthcare.

Disclaimer

All Rights Reserved No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData

Covance IncCovance Inc, Medical Devices Deals, 2011 to YTD 2017 Covance Inc, Medical Devices Deals,...

Documents

Transcript of Covance IncCovance Inc, Medical Devices Deals, 2011 to YTD 2017 Covance Inc, Medical Devices Deals,...